Procrit Scrutinized For Safety, Marketing
The news of the May 10 subpoena, which the company disclosed in its Wednesday filing with the U.S. Securities and Exchange Commission, is similar to previously disclosed information requests from Congress about the drug.
“Like the House and Senate requests, the subpoena asks for materials relating to Procrit safety, marketing and pricing. The company is responding,” J&J said. The company's Ortho...
To view the full article, register now.